Pfizer to acquire migraine firm for over USD 11bn
US-based Pfizer is prepared to pay as much as USD 11.6bn to buy Biohaven Pharmaceuticals and its approved migraine therapy.
by Benjamin Werner Christensen, translated by daniel pedersen
On Tuesday, Pfizer has announced its intention to acquire Biohaven Pharmaceuticals, agreeing to pay USD 148.5 per share in cash, which equals to a whopping price tag of USD 11.6bn, a company press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck's migraine drug approved in EU
For subscribers
.jpg&w=384&q=75)
